Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William M Greenberg

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Psychopharmacology Bulletin|December 17, 2003
Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and updateNunzio Pomara, William M Greenberg, Michael D Branford, et al.
Clinical Drug Investigation|September 4, 2013
Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension studyRajnish Mago, Giovanna Forero, William M Greenberg, et al.
CNS Spectrums|June 6, 2014
Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trialsStuart A Montgomery, Carl P Gommoll, Changzheng Chen, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|June 26, 2003
A survey of addiction training programming in psychiatry residenciesWilliam M Greenberg, Jonathan I Ritvo, Lydia Fazzio, et al.
Innovations in Clinical Neuroscience|March 22, 2014
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive DisorderThomas Shiovitz, William M Greenberg, Changzheng Chen, et al.
The Journal of Clinical Psychiatry|April 9, 2013
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled studyGregory M Asnis, Anjana Bose, Carl P Gommoll, et al.
The Primary Care Companion for CNS Disorders|December 9, 2015
Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment CategoriesAndrew J Cutler, Carl P Gommoll, Changzheng Chen, et al.
Clinical Drug Investigation|March 29, 2014
Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participantsLaishun Chen, Ramesh Boinpally, William M Greenberg, et al.
Drug Design, Development and Therapy|July 8, 2015
Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humansLaishun Chen, William M Greenberg, Elimor Brand-Schieber, et al.
International Clinical Psychopharmacology|November 20, 2015
Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorderMarlene P Freeman, Maurizio Fava, Carl Gommoll, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Psychopharmacology Bulletin|December 17, 2003
Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and updateNunzio Pomara, William M Greenberg, Michael D Branford, et al.
Clinical Drug Investigation|September 4, 2013
Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension studyRajnish Mago, Giovanna Forero, William M Greenberg, et al.
CNS Spectrums|June 6, 2014
Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trialsStuart A Montgomery, Carl P Gommoll, Changzheng Chen, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|June 26, 2003
A survey of addiction training programming in psychiatry residenciesWilliam M Greenberg, Jonathan I Ritvo, Lydia Fazzio, et al.
Innovations in Clinical Neuroscience|March 22, 2014
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive DisorderThomas Shiovitz, William M Greenberg, Changzheng Chen, et al.
The Journal of Clinical Psychiatry|April 9, 2013
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled studyGregory M Asnis, Anjana Bose, Carl P Gommoll, et al.
The Primary Care Companion for CNS Disorders|December 9, 2015
Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment CategoriesAndrew J Cutler, Carl P Gommoll, Changzheng Chen, et al.
Clinical Drug Investigation|March 29, 2014
Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participantsLaishun Chen, Ramesh Boinpally, William M Greenberg, et al.
Drug Design, Development and Therapy|July 8, 2015
Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humansLaishun Chen, William M Greenberg, Elimor Brand-Schieber, et al.
International Clinical Psychopharmacology|November 20, 2015
Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorderMarlene P Freeman, Maurizio Fava, Carl Gommoll, et al.
Pageof 3